Literature DB >> 14976890

[Effect of anti-fibrosis compound contained serum on procollagen Type I and IV, matrix metalloproteinase and its tissue inhibitor-1 gene expression in HSC-LI90 cell line].

Gang Zhao1, Ling-tai Wang, Jian-jie Chen.   

Abstract

OBJECTIVE: To study the effects of Anti-fibrosis Compound contained serum (AFCS) on procollagen type I and IV (ProC-I and ProC-IV), matrix metalloproteinase (MMP) and its tissue inhibitor (TIMP-1) gene expression in hepatic stellate cell line LI90 (HSC-LI90).
METHODS: AFCS was prepared by gastric infusing different dosage (0.5 g/kg, 2.0 g/kg and 4.0 g/kg) of Anti-fibrosis Compound Recipe to rats. After HSC-LI90 cells were exposed to AFCS for 48 hrs, levels of ProC-I, ProC-IV, gene expression of MMP-2, MMP membrane type 1 (MT1-MMP) and TIMP-1 in the cells were detected by Northern blot, and gelatinase activity of MMP-2 was measured by zymography.
RESULTS: AFCS of different concentrations could inhibit ProC-I and ProC-IV and TIMP-1 gene expression (P < 0.05 or P < 0.01), increase MT1-MMP gene expression (P < 0.01), but it showed no effect on gene expression and activity of MMP-2 (P > 0.05).
CONCLUSION: Anti-fibrosis Compound Recipe has anti-liver fibrosis action, its effects in inhibiting TIMP-1 gene expression of HSC-LI90 cells and promoting degradation of collagen might be one of the mechanisms of the action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976890

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Effects of pharmacological serum from normal and liver fibrotic rats on HSCs.

Authors:  Xi-Xian Yao; Tao Lv
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

2.  Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jing-Hao Zhang; Xin Zhang; Zhen-Hua Zhou; Xiao-Jun Zhu; Chao Zheng; Man Li; Shu-Gen Jin; De-Wen Mao; Jing-Dong Xue; Wei-Bing Shi; Xiao-Ling Chi; Xian-Bo Wang; Xiao-Dong Li; Yong Li; Hui Wang; Qin Li; Da-Qiao Zhou; Cheng-Bao Wang; Chang-He Shi; Cheng-Zhong Li; Jian-Hua Wu; Xiao-Ni Kong; Xue-Hua Sun; Yue-Qiu Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.